Pub Date : 2025-10-01Epub Date: 2024-06-26DOI: 10.1016/j.rcreu.2024.04.009
Emine Öztürk , Dilara Bulut Gökten , Rıdvan Mercan , Savaş Güzel
<div><h3>Introduction/Objective</h3><div>In our study, we investigated the role of Parkinsonism-associated protein 7 (PARK-7), known as DJ-1, which is involved in several pathways that counteract oxidative stress. This stress is thought to contribute to the development of fibrosis<span> and vascular damage in patients with systemic sclerosis (SSc). Our study aims to investigate the correlation between PARK-7 levels, laboratory and clinical findings related to SSc and treatment regimens.</span></div></div><div><h3>Materials and methods</h3><div>In our study, we included fifty patients aged 18 years and older diagnosed with SSc and thirty healthy individuals without any systemic, malignant, or autoimmune diseases as a control group. We collected demographic data, clinical manifestations, laboratory and radiological findings, pulmonary function test (PFT), and echocardiography reports, information on comorbidities and prescribed medications from medical records, hospital database analysis, and direct patient interviews. Disease activity was quantified and documented using activity scoring systems developed by the European Scleroderma Study Group (EScSG) and the United Kingdom's (UK) Functional Activity Scoring. PARK-7 levels in venous blood samples from participating patients were quantified by Enzyme-Linked Immunosorbent Assay (ELISA).</div></div><div><h3>Results</h3><div>The PARK-7 level was 21.26<!--> <!-->±<!--> <!-->15.83 in the patient group and 16.11<!--> <!-->±<!--> <!-->11.83 in the control group. There was no significant difference in PARK-7 levels between the patient and control groups (<em>p</em> <!-->=<!--> <!-->.22). In terms of disease subtypes, PARK-7 levels were 21.35<!--> <!-->±<!--> <!-->18.36 in the limited form, 23.18<!--> <!-->±<!--> <!-->13.83 in the diffuse form. No statistically significant differences were observed between PARK-7 levels, the control group, and the different disease forms (<em>p</em> <!-->><!--> <span>.05). In patients classified as having active disease according to the EScSG scoring system, the PARK-7 level was 25.69</span> <!-->±<!--> <!-->18.10 compared to 16.00<!--> <!-->±<!--> <!-->10.91 in the inactive group. No significant correlation was found between the presence of high-resolution computed tomography (HRCT) findings, other systemic involvement, and PARK-7 levels.</div></div><div><h3>Conclusions</h3><div>Over the past decade, numerous reports have highlighted the therapeutic potential of PARK-7 and its related molecules for the treatment of various diseases. Whether PARK-7 can be effectively used in the treatment of SSc remains unclear due to the cross-sectional design of our study. We believe that a study measuring PARK-7 levels in patients newly diagnosed or in the early stages of SSc, followed by randomised and prospective follow-up of clinical outcomes with and without treatment, could significantly improve our understanding of the role of PARK-7 in the pathogenesis of SSc and its potential
{"title":"Retrospective evaluation of PARK-7 expression dynamics in systemic sclerosis","authors":"Emine Öztürk , Dilara Bulut Gökten , Rıdvan Mercan , Savaş Güzel","doi":"10.1016/j.rcreu.2024.04.009","DOIUrl":"10.1016/j.rcreu.2024.04.009","url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>In our study, we investigated the role of Parkinsonism-associated protein 7 (PARK-7), known as DJ-1, which is involved in several pathways that counteract oxidative stress. This stress is thought to contribute to the development of fibrosis<span> and vascular damage in patients with systemic sclerosis (SSc). Our study aims to investigate the correlation between PARK-7 levels, laboratory and clinical findings related to SSc and treatment regimens.</span></div></div><div><h3>Materials and methods</h3><div>In our study, we included fifty patients aged 18 years and older diagnosed with SSc and thirty healthy individuals without any systemic, malignant, or autoimmune diseases as a control group. We collected demographic data, clinical manifestations, laboratory and radiological findings, pulmonary function test (PFT), and echocardiography reports, information on comorbidities and prescribed medications from medical records, hospital database analysis, and direct patient interviews. Disease activity was quantified and documented using activity scoring systems developed by the European Scleroderma Study Group (EScSG) and the United Kingdom's (UK) Functional Activity Scoring. PARK-7 levels in venous blood samples from participating patients were quantified by Enzyme-Linked Immunosorbent Assay (ELISA).</div></div><div><h3>Results</h3><div>The PARK-7 level was 21.26<!--> <!-->±<!--> <!-->15.83 in the patient group and 16.11<!--> <!-->±<!--> <!-->11.83 in the control group. There was no significant difference in PARK-7 levels between the patient and control groups (<em>p</em> <!-->=<!--> <!-->.22). In terms of disease subtypes, PARK-7 levels were 21.35<!--> <!-->±<!--> <!-->18.36 in the limited form, 23.18<!--> <!-->±<!--> <!-->13.83 in the diffuse form. No statistically significant differences were observed between PARK-7 levels, the control group, and the different disease forms (<em>p</em> <!-->><!--> <span>.05). In patients classified as having active disease according to the EScSG scoring system, the PARK-7 level was 25.69</span> <!-->±<!--> <!-->18.10 compared to 16.00<!--> <!-->±<!--> <!-->10.91 in the inactive group. No significant correlation was found between the presence of high-resolution computed tomography (HRCT) findings, other systemic involvement, and PARK-7 levels.</div></div><div><h3>Conclusions</h3><div>Over the past decade, numerous reports have highlighted the therapeutic potential of PARK-7 and its related molecules for the treatment of various diseases. Whether PARK-7 can be effectively used in the treatment of SSc remains unclear due to the cross-sectional design of our study. We believe that a study measuring PARK-7 levels in patients newly diagnosed or in the early stages of SSc, followed by randomised and prospective follow-up of clinical outcomes with and without treatment, could significantly improve our understanding of the role of PARK-7 in the pathogenesis of SSc and its potential ","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 4","pages":"Pages 309-314"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2024-08-01DOI: 10.1016/j.rcreu.2024.05.003
Luz Elena Triana Vidal, Armando Lucumi Moreno, Ivonne Valeria Ortiz
Introduction
Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and cellular antioxidant activity. Overproduction of ROS causes oxidative damage to major macromolecules, alters homeostasis and leads to the generation of different pathologies. At present, there is no totally effective treatment to counteract these diseases involved with oxidative stress, so it is necessary to investigate new treatment alternatives that suppress the ROS generated. One promising alternative is the use of plant extracts, which have demonstrated a potent antioxidant effect. Efficient cells for the study of pathological diseases related to reactive oxygen species are T lymphocytes, which share systems with neurons such as: the dopaminergic system, death signaling and survival. In vitro lymphocytes are an optimal model for the evaluation of oxidative mechanisms.
Objective
To determine the protective effect of ethanolic extract of propolis against oxidative damage induced by hydrogen peroxide (H2O2) in human lymphocytes in vitro, by means of the cell viability test with trypan blue.
Results
Anova test shows that the concentrations of 0.0225 and 0.045 mg/mL of ethanolic extract of propolis, present protective activity against cell damage caused by H2O2.
Conclusion
This study proposes the ethanolic extract of propolis as a potential pharmacological, useful for treatments against autoimmune disorders.
{"title":"Efecto protector de propóleo frente al daño oxidativo inducido con peróxido de hidrógeno en células mononucleares de sangre periférica cultivadas in vitro mediante conteo celular","authors":"Luz Elena Triana Vidal, Armando Lucumi Moreno, Ivonne Valeria Ortiz","doi":"10.1016/j.rcreu.2024.05.003","DOIUrl":"10.1016/j.rcreu.2024.05.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and cellular antioxidant activity. Overproduction of ROS causes oxidative damage to major macromolecules, alters homeostasis and leads to the generation of different pathologies. At present, there is no totally effective treatment to counteract these diseases involved with oxidative stress, so it is necessary to investigate new treatment alternatives that suppress the ROS generated. One promising alternative is the use of plant extracts, which have demonstrated a potent antioxidant effect. Efficient cells for the study of pathological diseases related to reactive oxygen species are T<!--> <!-->lymphocytes, which share systems with neurons such as: the dopaminergic system, death signaling and survival. In vitro lymphocytes are an optimal model for the evaluation of oxidative mechanisms.</div></div><div><h3>Objective</h3><div>To determine the protective effect of ethanolic extract of propolis against oxidative damage induced by hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in human lymphocytes in vitro, by means of the cell viability test with trypan blue.</div></div><div><h3>Results</h3><div>Anova test shows that the concentrations of 0.0225 and 0.045<!--> <!-->mg/mL of ethanolic extract of propolis, present protective activity against cell damage caused by H<sub>2</sub>O<sub>2</sub>.</div></div><div><h3>Conclusion</h3><div>This study proposes the ethanolic extract of propolis as a potential pharmacological, useful for treatments against autoimmune disorders.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 4","pages":"Pages 315-320"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2024-08-08DOI: 10.1016/j.rcreu.2024.06.001
Ana Ospina-Caicedo , Beatriz Eugenia Bastidas Sánchez , Daniel Camilo Bastidas Burbano , Andrea Milena Villota Enríquez , María Fernanda Muñoz Rivera , Cristian Alfonso Campo Guzmán
Introduction
Systemic lupus erythematosus (SLE) is a chronic and systemic autoimmune disease, to which high morbidity and mortality are attributed that affect quality of life.
Objective
To estimate the quality of life of patients hospitalized with SLE in a tertiary institution in Colombia.
Materials and methods
Descriptive, observational cross-sectional design of patients with SLE, hospitalized between July 2022 and January 2023, to whom an instrument that included the SF-36 quality of life scale was applied.
Results
Forty-four patients were included, with an average age of 37 years, 88.6% women. The main cause of hospitalization was disease activity at 61.3%. The physical role was the most affected with an average of 23.5 points and 78.9% of the participants had deterioration in physical functioning, especially among women, mixed race, with more than one year from diagnosis and independently of the manifestations of the disease. The dimension of health change and social role were especially affected in patients with moderate to high activity, and the use of glucocorticoids was related to this negative impact on health change.
Conclusion
It is necessary to study the quality of life in hospitalized patients with SLE for a comprehensive approach to treatment, taking into account that physical role and functioning are the dimensions most affected globally, and that the health change and social role dimensions are the most affected in those with moderate to high disease activity.
{"title":"Estimación de la calidad de vida en pacientes hospitalizados con lupus eritematoso sistémico en una institución de tercer nivel en Colombia","authors":"Ana Ospina-Caicedo , Beatriz Eugenia Bastidas Sánchez , Daniel Camilo Bastidas Burbano , Andrea Milena Villota Enríquez , María Fernanda Muñoz Rivera , Cristian Alfonso Campo Guzmán","doi":"10.1016/j.rcreu.2024.06.001","DOIUrl":"10.1016/j.rcreu.2024.06.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) is a chronic and systemic autoimmune disease, to which high morbidity and mortality are attributed that affect quality of life.</div></div><div><h3>Objective</h3><div>To estimate the quality of life of patients hospitalized with SLE in a tertiary institution in Colombia.</div></div><div><h3>Materials and methods</h3><div>Descriptive, observational cross-sectional design of patients with SLE, hospitalized between July 2022 and January 2023, to whom an instrument that included the SF-36 quality of life scale was applied.</div></div><div><h3>Results</h3><div>Forty-four patients were included, with an average age of 37 years, 88.6% women. The main cause of hospitalization was disease activity at 61.3%. The physical role was the most affected with an average of 23.5 points and 78.9% of the participants had deterioration in physical functioning, especially among women, mixed race, with more than one year from diagnosis and independently of the manifestations of the disease. The dimension of health change and social role were especially affected in patients with moderate to high activity, and the use of glucocorticoids was related to this negative impact on health change.</div></div><div><h3>Conclusion</h3><div>It is necessary to study the quality of life in hospitalized patients with SLE for a comprehensive approach to treatment, taking into account that physical role and functioning are the dimensions most affected globally, and that the health change and social role dimensions are the most affected in those with moderate to high disease activity.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 4","pages":"Pages 335-343"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2024-08-08DOI: 10.1016/j.rcreu.2024.06.002
Juan Camilo Pérez-Correa , Darwin Jhoan Ariza-Rodríguez , María Claudia Díaz-Jiménez , Daniel G. Fernández-Ávila , Juan Martín Gutiérrez , Diego Rosselli
Introduction
Systemic lupus erythematosus (SLE) entails high direct medical costs, derived from the complexity of diagnosis, treatment, and management of associated complications. In Colombia, there are studies on direct outpatient medical costs, and hospital studies are scarce.
Objective
The present study describes the direct medical costs derived from hospital care in a high complexity hospital in Bogotá.
Materials and methods
Observational, retrospective, partial economic study. A descriptive analysis of the direct medical costs of caring for hospitalized patients with SLE was performed. The data was obtained by reviewing medical records between January and December 2019; Cost data were taken from the amounts billed by the hospital. Costs in Colombian pesos were expressed in dollars.
Results
Costs of 68 patients and 100 hospitalizations were analysed. The mean age was 39 years ± 12.4. The mean hospital stay was 6.8 days ± 6.1. Total direct medical costs were 267,980 USD with a median per hospitalization of 1,622 USD. Non-surgical procedures represented 64% of the costs (170,708 USD), drugs 25% (67,494 USD), medical supplies and procedures 9% (24,936 USD), and 2% (4,842 USD) respectively.
Conclusion
Hospitalizations of patients with SLE entail high direct medical costs, which do not differ significantly from hospital costs in other countries. Non-surgical procedures and drugs accounted for the largest share of these costs, followed by supplies and surgical procedures.
{"title":"Costo de atención hospitalaria en pacientes con lupus eritematoso sistémico en un hospital de alta complejidad en Colombia","authors":"Juan Camilo Pérez-Correa , Darwin Jhoan Ariza-Rodríguez , María Claudia Díaz-Jiménez , Daniel G. Fernández-Ávila , Juan Martín Gutiérrez , Diego Rosselli","doi":"10.1016/j.rcreu.2024.06.002","DOIUrl":"10.1016/j.rcreu.2024.06.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) entails high direct medical costs, derived from the complexity of diagnosis, treatment, and management of associated complications. In Colombia, there are studies on direct outpatient medical costs, and hospital studies are scarce.</div></div><div><h3>Objective</h3><div>The present study describes the direct medical costs derived from hospital care in a high complexity hospital in Bogotá.</div></div><div><h3>Materials and methods</h3><div>Observational, retrospective, partial economic study. A descriptive analysis of the direct medical costs of caring for hospitalized patients with SLE was performed. The data was obtained by reviewing medical records between January and December 2019; Cost data were taken from the amounts billed by the hospital. Costs in Colombian pesos were expressed in dollars.</div></div><div><h3>Results</h3><div>Costs of 68 patients and 100 hospitalizations were analysed. The mean age was 39 years<!--> <!-->±<!--> <!-->12.4. The mean hospital stay was 6.8 days<!--> <!-->±<!--> <!-->6.1. Total direct medical costs were 267,980 USD with a median per hospitalization of 1,622 USD. Non-surgical procedures represented 64% of the costs (170,708 USD), drugs 25% (67,494 USD), medical supplies and procedures 9% (24,936 USD), and 2% (4,842 USD) respectively.</div></div><div><h3>Conclusion</h3><div>Hospitalizations of patients with SLE entail high direct medical costs, which do not differ significantly from hospital costs in other countries. Non-surgical procedures and drugs accounted for the largest share of these costs, followed by supplies and surgical procedures.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 4","pages":"Pages 344-350"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2024-09-05DOI: 10.1016/j.rcreu.2024.07.004
Kaori Mitchell Gil-Rivasplata, Valeria Katiuska Rojas-Del Aguila, Carlos Manuel Escobar-Galindo, Jesús Martin Trinidad-López
Introduction/objective
Rheumatoid arthritis (RA) primarily affects the hand joints, limiting independence for feeding and requiring the use of assistive technology. The thickening of the handles on the spoon is used as a treatment strategy. However, few studies address how much it helps in RA. Therefore, the study aimed to determine the effect of the use of thickened handle spoons on time, performance quality, and perceived hand effort in the improvement of feeding in users simulating RA with restricted han
d movements.
Materials and methods
A quasi-experimental design was used in which RA was simulated with a simulator glove, comparing feeding experiences with regular spoons.
Results
Using spoons with thickened handles had statistically significant effects on the reduction of perceived effort when eating different foods (p = .005); however, there was no significant difference between the number of times food was dropped and the time to complete the activity (p = .78).
Conclusions
Spoons with thickened handles reduce the level of perceived effort, which allows for better joint protection and pain management. It also equals the time and efficiency of eating with a conventional spoon.
{"title":"Uso de cucharas con mango engrosado en la mejora del desempeño para la alimentación en pacientes con artritis reumatoide","authors":"Kaori Mitchell Gil-Rivasplata, Valeria Katiuska Rojas-Del Aguila, Carlos Manuel Escobar-Galindo, Jesús Martin Trinidad-López","doi":"10.1016/j.rcreu.2024.07.004","DOIUrl":"10.1016/j.rcreu.2024.07.004","url":null,"abstract":"<div><h3>Introduction/objective</h3><div>Rheumatoid arthritis (RA) primarily affects the hand joints, limiting independence for feeding and requiring the use of assistive technology. The thickening of the handles on the spoon is used as a treatment strategy. However, few studies address how much it helps in RA. Therefore, the study aimed to determine the effect of the use of thickened handle spoons on time, performance quality, and perceived hand effort in the improvement of feeding in users simulating RA with restricted han</div><div>d movements.</div></div><div><h3>Materials and methods</h3><div>A quasi-experimental design was used in which RA was simulated with a simulator glove, comparing feeding experiences with regular spoons.</div></div><div><h3>Results</h3><div>Using spoons with thickened handles had statistically significant effects on the reduction of perceived effort when eating different foods (p<!--> <!-->=<!--> <!-->.005); however, there was no significant difference between the number of times food was dropped and the time to complete the activity (p<!--> <!-->=<!--> <!-->.78).</div></div><div><h3>Conclusions</h3><div>Spoons with thickened handles reduce the level of perceived effort, which allows for better joint protection and pain management. It also equals the time and efficiency of eating with a conventional spoon.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 4","pages":"Pages 351-358"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2024-08-05DOI: 10.1016/j.rcreu.2024.05.006
Luis Javier Cajas Santana , Daniela Rojas Carvajal , Wendy Torres Chazatar , Laura Mendoza Galindo , Yensi Romero Díaz , Daniel Ramírez Muñoz , Gisella Fernández Salamanca
Introduction
Interstitial lung disease is a significant complication in autoimmune diseases. The extent of involvement is crucial in determining both onset and treatment response. While there are computational methods for this calculation, manual methods, such as the Goh method, remain the most commonly used. However, it has some disadvantages, such as presuming that areas across the lung are equivalent and thus influence the calculation equally. The aim of this study is to analyse these difficulties and find a mathematical correction method.
Materials and Methods
High-resolution chest tomography images were obtained from patients with and without ILD. Pulmonary areas were analysed and compared in the slices referenced in the Goh method. Through geometric analysis of lung structure, the slice closest to the average of its areas was identified for comparison with other measurements. Based on this, a correction equation was formulated, and through simulation of various interstitial involvement patterns, the degree of variation was determined.
Results
Images from 80 patients were analysed, mostly women diagnosed with systemic sclerosis. It was found that apical areas (slices 1 and 2) and the sum of left-sided pulmonary areas were 20% smaller compared to basal and right-sided areas, respectively. Simulation with different involvement components found that apical or left-sided disease overestimates extension by 5% to 10%, especially when it exceeds 15%. The third slice was determined to be closest to the average of the areas, and a correction formula was devised based on this.
Conclusions
The Goh method incorrectly assumes the equivalence of pulmonary areas, which can impact calculations. We propose a mathematical correction for this purpose.
{"title":"Análisis de las desigualdades y modelo de corrección del método de Goh usado en la cuantificación de la enfermedad pulmonar intersticial","authors":"Luis Javier Cajas Santana , Daniela Rojas Carvajal , Wendy Torres Chazatar , Laura Mendoza Galindo , Yensi Romero Díaz , Daniel Ramírez Muñoz , Gisella Fernández Salamanca","doi":"10.1016/j.rcreu.2024.05.006","DOIUrl":"10.1016/j.rcreu.2024.05.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Interstitial lung disease is a significant complication in autoimmune diseases. The extent of involvement is crucial in determining both onset and treatment response. While there are computational methods for this calculation, manual methods, such as the Goh method, remain the most commonly used. However, it has some disadvantages, such as presuming that areas across the lung are equivalent and thus influence the calculation equally. The aim of this study is to analyse these difficulties and find a mathematical correction method.</div></div><div><h3>Materials and Methods</h3><div>High-resolution chest tomography images were obtained from patients with and without ILD. Pulmonary areas were analysed and compared in the slices referenced in the Goh method. Through geometric analysis of lung structure, the slice closest to the average of its areas was identified for comparison with other measurements. Based on this, a correction equation was formulated, and through simulation of various interstitial involvement patterns, the degree of variation was determined.</div></div><div><h3>Results</h3><div>Images from 80 patients were analysed, mostly women diagnosed with systemic sclerosis. It was found that apical areas (slices 1 and 2) and the sum of left-sided pulmonary areas were 20% smaller compared to basal and right-sided areas, respectively. Simulation with different involvement components found that apical or left-sided disease overestimates extension by 5% to 10%, especially when it exceeds 15%. The third slice was determined to be closest to the average of the areas, and a correction formula was devised based on this.</div></div><div><h3>Conclusions</h3><div>The Goh method incorrectly assumes the equivalence of pulmonary areas, which can impact calculations. We propose a mathematical correction for this purpose.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 4","pages":"Pages 328-334"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2024-06-25DOI: 10.1016/j.rcreu.2024.04.008
Julio Roberto Amador , Carolina Becerra-Arias , Wilmer Gerardo Rojas-Zuleta , Juan Raul Castro-Ayarza , Manuel Franco , Mario Barbosa-Rengifo , Jorge Donado-Gómez , Natalia Duque-Zapata
<div><h3>Introduction</h3><div>Psoriasis is a chronic inflammatory disease characterized by scaly erythematous plaques, systemic inflammation, and an elevated cardiovascular risk. Due to its complexity in treatment and the frequent occurrence of comorbidities, characterizing patients diagnosed with psoriasis enrolled in care programmes becomes paramount for enhancing health outcomes.</div></div><div><h3>Objective</h3><div>To provide a comprehensive description of the sociodemographic, clinical features, and outcomes of a cohort of patients diagnosed with psoriasis in a multicentre outpatient healthcare institution in Colombia.</div></div><div><h3>Materials and methods</h3><div>A cohort study was conducted involving patients diagnosed with psoriasis. Inclusion criteria required a minimum follow-up duration of three months. Quantitative variables were summarized using the median and interquartile range, while qualitative variables were presented with measures of frequency and 95% confidence interval. Changes in the final values of PASI<span>, DLQI<span>, NAPSI<span>, and BSA from baselines were assessed through percentage comparisons, analysed using chi-square test.</span></span></span></div></div><div><h3>Results</h3><div>A total of 1155 patients were included, with a median age of 53 years and the majority were men (58%). Plaque psoriasis was the predominant type, observed in 78.7%. Psoriatic arthritis was diagnosed in 18.9%. The most prevalent comorbidity was hypertension, identified in 23.0% (95% CI 20.6 to 25.6%), followed by diabetes at 12.5% (95% CI 10.6 to 14.5%) and cardiovascular disease at 10.6%. A significant proportion of patients were classified as overweight and obese, 43.9% (n<!--> <!-->=<!--> <!-->479) and 20.9% (n<!--> <!-->=<!--> <!-->228), respectively. Regarding treatment modalities, the majority received biological therapies (39%), followed by systemic therapy (22.2%), and topical therapy (17.5%).</div><div>During the follow-up period, a considerable percentage of patients experienced some decrease in disease activity. A PASI75 response was achieved by 28.5% (95% CI 25.4% to 31.8%), and PASI90% was achieved by 18% (95% CI 15.4% to 20.9%). A bivariate analysis based on Body Mass Index showed a lower response in patients with overweight or obesity, thought these differences were not statistically significant (p<!--> <!-->=<!--> <!-->.937). Notably, a higher percentage of patients with no response were observed among those with hypertension (62.9% p<!--> <!-->=<!--> <!-->.123), diabetes mellitus (64.7% p<!--> <!-->=<!--> <!-->.393), cardiovascular disease (51.5% p<<!--> <!-->.001), and chronic kidney disease (55.6% p<!--> <!-->=<!--> <!-->.014) when compared with patients who achieved therapeutic goals.</div></div><div><h3>Conclusions</h3><div>We present the largest psoriasis cohort in Colombia. A majority of our patients showed improvement in disease activity based on clinimetric measures. Nevertheless, the presence of comorb
银屑病是一种慢性炎症性疾病，以鳞状红斑斑块、全身炎症和心血管风险升高为特征。由于其治疗的复杂性和合并症的频繁发生，诊断为牛皮癣的患者的特征登记在护理方案中成为提高健康结果的重要因素。目的：对哥伦比亚一家多中心门诊医疗机构诊断为牛皮癣的一组患者的社会人口学、临床特征和结果进行全面描述。材料与方法对诊断为牛皮癣的患者进行了一项队列研究。纳入标准要求至少随访3个月。定量变量用中位数和四分位数范围来概括，而定性变量用频率和95%置信区间来表示。PASI、DLQI、NAPSI和BSA最终值与基线的变化通过百分比比较进行评估，使用卡方检验进行分析。结果共纳入1155例患者，中位年龄53岁，男性居多（58%）。斑块型银屑病为主要类型，占78.7%。诊断为银屑病关节炎的占18.9%。最常见的合并症是高血压，占23.0% (95% CI 20.6 - 25.6%)，其次是糖尿病，占12.5% (95% CI 10.6 - 14.5%)，心血管疾病占10.6%。超重和肥胖患者占比显著，分别为43.9% （n = 479）和20.9% （n = 228）。在治疗方式方面，大多数接受生物治疗（39%），其次是全身治疗（22.2%）和局部治疗（17.5%）。在随访期间，相当一部分患者的疾病活动有所减少。PASI75缓解率为28.5% (95% CI 25.4%至31.8%)，PASI90%缓解率为18% （95% CI 15.4%至20.9%）。基于身体质量指数的双变量分析显示，超重或肥胖患者的反应较低，尽管这些差异没有统计学意义（p = .937）。值得注意的是，与达到治疗目标的患者相比，高血压（62.9% p = .123）、糖尿病（64.7% p = .393）、心血管疾病（51.5% p = .001）和慢性肾脏疾病（55.6% p = .014）患者无反应的比例更高。结论：我们提出了哥伦比亚最大的牛皮癣队列。根据临床测量，我们的大多数患者表现出疾病活动度的改善。然而，合并症的存在显著降低了获得治疗反应的可能性。多学科方法结合严密的随访可确保更好的结果，突出了实施现实世界的多学科护理规划的重要性。
{"title":"Clinical characteristic and outcomes of psoriasis patients in a multicentre outpatient healthcare institution in Colombia","authors":"Julio Roberto Amador , Carolina Becerra-Arias , Wilmer Gerardo Rojas-Zuleta , Juan Raul Castro-Ayarza , Manuel Franco , Mario Barbosa-Rengifo , Jorge Donado-Gómez , Natalia Duque-Zapata","doi":"10.1016/j.rcreu.2024.04.008","DOIUrl":"10.1016/j.rcreu.2024.04.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Psoriasis is a chronic inflammatory disease characterized by scaly erythematous plaques, systemic inflammation, and an elevated cardiovascular risk. Due to its complexity in treatment and the frequent occurrence of comorbidities, characterizing patients diagnosed with psoriasis enrolled in care programmes becomes paramount for enhancing health outcomes.</div></div><div><h3>Objective</h3><div>To provide a comprehensive description of the sociodemographic, clinical features, and outcomes of a cohort of patients diagnosed with psoriasis in a multicentre outpatient healthcare institution in Colombia.</div></div><div><h3>Materials and methods</h3><div>A cohort study was conducted involving patients diagnosed with psoriasis. Inclusion criteria required a minimum follow-up duration of three months. Quantitative variables were summarized using the median and interquartile range, while qualitative variables were presented with measures of frequency and 95% confidence interval. Changes in the final values of PASI<span>, DLQI<span>, NAPSI<span>, and BSA from baselines were assessed through percentage comparisons, analysed using chi-square test.</span></span></span></div></div><div><h3>Results</h3><div>A total of 1155 patients were included, with a median age of 53 years and the majority were men (58%). Plaque psoriasis was the predominant type, observed in 78.7%. Psoriatic arthritis was diagnosed in 18.9%. The most prevalent comorbidity was hypertension, identified in 23.0% (95% CI 20.6 to 25.6%), followed by diabetes at 12.5% (95% CI 10.6 to 14.5%) and cardiovascular disease at 10.6%. A significant proportion of patients were classified as overweight and obese, 43.9% (n<!--> <!-->=<!--> <!-->479) and 20.9% (n<!--> <!-->=<!--> <!-->228), respectively. Regarding treatment modalities, the majority received biological therapies (39%), followed by systemic therapy (22.2%), and topical therapy (17.5%).</div><div>During the follow-up period, a considerable percentage of patients experienced some decrease in disease activity. A PASI75 response was achieved by 28.5% (95% CI 25.4% to 31.8%), and PASI90% was achieved by 18% (95% CI 15.4% to 20.9%). A bivariate analysis based on Body Mass Index showed a lower response in patients with overweight or obesity, thought these differences were not statistically significant (p<!--> <!-->=<!--> <!-->.937). Notably, a higher percentage of patients with no response were observed among those with hypertension (62.9% p<!--> <!-->=<!--> <!-->.123), diabetes mellitus (64.7% p<!--> <!-->=<!--> <!-->.393), cardiovascular disease (51.5% p<<!--> <!-->.001), and chronic kidney disease (55.6% p<!--> <!-->=<!--> <!-->.014) when compared with patients who achieved therapeutic goals.</div></div><div><h3>Conclusions</h3><div>We present the largest psoriasis cohort in Colombia. A majority of our patients showed improvement in disease activity based on clinimetric measures. Nevertheless, the presence of comorb","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 4","pages":"Pages 301-308"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-09-10DOI: 10.1016/j.rcreu.2025.08.001
Bibiana Andrea Pinzón Valderrama
{"title":"Hacia una cuantificación más precisa de la fibrosis pulmonar en esclerodermia: reflexiones sobre el método de Goh y su corrección geométrica","authors":"Bibiana Andrea Pinzón Valderrama","doi":"10.1016/j.rcreu.2025.08.001","DOIUrl":"10.1016/j.rcreu.2025.08.001","url":null,"abstract":"","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 4","pages":"Pages 299-300"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01Epub Date: 2024-12-10DOI: 10.1016/j.rcreu.2024.09.003
Yimy F. Medina, Antonio Iglesias Gamarra
Introduction
The Rheumatology Unit of the National University of Colombia (UNAL) has a history spanning over half a century, producing many prominent rheumatologists. This article provides a description of its history to understand its trajectory, historical context, challenges, achievements, and contributions.
Reflections
In 1960, the Rheumatology Section at UNAL was officially approved, founded by professors Mario Peña, Humberto Lizarazo, and Fernando Chalem. In 1962, Drs. Peña, Chalem, and Lizarazo established the Rheumatology Service at San Juan de Dios Hospital. In 1963, the outpatient clinic for rheumatic patients began operating at the same hospital. Dr. Enrique Clavijo Acero became the first rheumatologist qualified through a Colombian university in 1971. By 1973, various specialty programmes at UNAL, including rheumatology, were officially approved, and the Rheumatology Unit was elevated to the status of a section.
Discussion
For more than 50 years, the Rheumatology Unit has trained medical students and specialists, who have played a critical role in the field. It remains a vital part of rheumatology both in Colombia and the region.
Conclusion
The Rheumatology Unit at the National University of Colombia, as the first academic institution in this field within the country, celebrates over 60 years of activity and 50 years of official recognition. It has achieved numerous milestones and has been a pioneering force in rheumatology.
哥伦比亚国立大学风湿病科（UNAL）有半个多世纪的历史，培养了许多杰出的风湿病学家。本文提供了对其历史的描述，以了解其发展轨迹、历史背景、挑战、成就和贡献。1960年，由Mario Peña、Humberto Lizarazo和Fernando Chalem教授成立的UNAL风湿病科正式批准成立。1962年。Peña， Chalem和Lizarazo在San Juan de Dios医院建立了风湿病服务中心。1963年，风湿病门诊在同一家医院开始营业。Enrique Clavijo Acero博士于1971年成为第一位通过哥伦比亚大学获得资格的风湿病学家。到1973年，UNAL的各种专业项目，包括风湿病学，得到正式批准，风湿病学股被提升到一个科的地位。讨论50多年来，风湿病科培养了医学学生和专家，他们在该领域发挥了关键作用。它仍然是哥伦比亚和该地区风湿病学的重要组成部分。哥伦比亚国立大学的风湿病学单位，作为国内该领域的第一个学术机构，庆祝了60多年的活动和50年的官方认可。它已经取得了许多里程碑，并已成为风湿病学的先驱力量。
{"title":"History of 50 years of the Rheumatology Service of Universidad Nacional de Colombia: The first in Colombia and a pioneer in Latin America","authors":"Yimy F. Medina, Antonio Iglesias Gamarra","doi":"10.1016/j.rcreu.2024.09.003","DOIUrl":"10.1016/j.rcreu.2024.09.003","url":null,"abstract":"<div><h3>Introduction</h3><div>The Rheumatology Unit of the National University of Colombia (UNAL) has a history spanning over half a century, producing many prominent rheumatologists. This article provides a description of its history to understand its trajectory, historical context, challenges, achievements, and contributions.</div></div><div><h3>Reflections</h3><div>In 1960, the Rheumatology Section at UNAL was officially approved, founded by professors Mario Peña, Humberto Lizarazo, and Fernando Chalem. In 1962, Drs. Peña, Chalem, and Lizarazo established the Rheumatology Service at San Juan de Dios Hospital. In 1963, the outpatient clinic for rheumatic patients began operating at the same hospital. Dr. Enrique Clavijo Acero became the first rheumatologist qualified through a Colombian university in 1971. By 1973, various specialty programmes at UNAL, including rheumatology, were officially approved, and the Rheumatology Unit was elevated to the status of a section.</div></div><div><h3>Discussion</h3><div>For more than 50 years, the Rheumatology Unit has trained medical students and specialists, who have played a critical role in the field. It remains a vital part of rheumatology both in Colombia and the region.</div></div><div><h3>Conclusion</h3><div>The Rheumatology Unit at the National University of Colombia, as the first academic institution in this field within the country, celebrates over 60 years of activity and 50 years of official recognition. It has achieved numerous milestones and has been a pioneering force in rheumatology.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 3","pages":"Pages 276-285"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144623334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：